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Over 30% of adult patients with pleural infection either die and/or require surgery. There is no 
robust means of predicting at baseline presentation which patients will suffer a poor clinical 
outcome. A validated risk prediction score would allow early identification of high-risk patients, 
potentially directing more aggressive treatment thereafter.  
 
Objectives 
To prospectively assess a previously described risk score (RAPID - Renal (urea), Age, fluid Purulence, 
Infection source, Dietary (albumin)) in adults with pleural infection. 
 
Methods 
Prospective observational cohort study recruiting patients undergoing treatment for pleural 
infection. RAPID score and risk category were calculated at baseline presentation. The primary 
outcome was mortality at 3 months; secondary outcomes were mortality at 12 months, length of 




Mortality data were available in 542 of 546 (99.3%) patients recruited. Overall mortality was 10% 
(54/542) at 3 months and 19% (102/542) at 12 months. The RAPID risk category predicted mortality 
at 3 months; low-risk (RAPID score 0-2) mortality 5/222 (2.3%, 95%CI 0.9 to 5.7), medium-risk 
(RAPID score 3-4) mortality 21/228 (9.2%, 95%CI 6.0 to 13.7), and high-risk (RAPID score 5-7) 
mortality 27/92 (29.3%, 95%CI 21.0 to 39.2). C-statistics for the score at 3 and 12 months were 0.78 
(95%CI 0.71 to 0.83) and 0.77 (95%CI 0.72 to 0.82) respectively.  
 
Conclusions 
The RAPID score stratifies adults with pleural infection according to increasing risk of mortality and 
should inform future research directed at improving outcomes in this patient population. 
 
Abstract word count: 249 
 





Pleural infection is common, affecting more than 60,000 patients each year in the United States 
and United Kingdom (1), and is increasing in both paediatric (2-4) and adult (5-7) populations. The 
condition is associated with poor clinical outcomes; all-comers mortality is around 20% (8-11) and 
unchanged over the last 20 years. Morbidity is significant, with 25% of patients requiring hospital 
admission for more than 1 month, and a median hospital stay of 12-15 days (8-11). Treatment costs 
are substantial, with care costing approximately USD 5000 per patient(12, 13), equating to around 
USD 400 million per annum (UK & US). 
 
Standard (“medical”) treatment for confirmed pleural infection includes broad-spectrum antibiotics 
(until microbiological identification and sensitivities are established) and drainage of infected 
pleural fluid, usually via chest tube (14, 15). More invasive treatment is recommended in those 
with poor initial response (14, 15). This involves surgical drainage, usually by video-assisted 
thoracoscopic surgery (VATS), but may require thoracotomy with decortication, rib resection, 
and/or open drainage in more complex cases (5, 16-19). The unselected use of surgical drainage in 
all cases of pleural infection cannot be justified as at least 70% of patients will recover with 
“medical” treatment alone (10, 11); and surgery is associated with significant morbidity including 
peri-operative and anesthetic mortality (20), conversion to thoracotomy (21-23), and long-term 
pain in up to 5% (24, 25).  
 
A newer semi-invasive strategy for pleural infection is the combined use of intrapleural tPA and 
DNase given via chest tube which has been shown to improve drainage and potentially reduce 
hospital stay and surgical requirement (11). This treatment is now widely used as “rescue” therapy 
in those failing initial medical treatment (26), but is associated with substantial costs of around USD 
1400 per patient (27). Thus, surgical drainage or combined intrapleural tPA and DNase are 
potentially useful treatments in pleural infection, but would be best used in selected patients in 
whom outcomes are poor with standard management. 
 
Several studies have attempted to identify factors associated with poor outcome in pleural 
infection, suggesting that fluid purulence (9), delayed access to surgery (28) and ultrasound 
parameters (29) may be associated with poor outcomes; results from these studies are not robust 
though given their retrospective designs. Only one study (30) has derived and retrospectively 
validated a clinical prediction rule in pleural infection (the RAPID score) in which baseline serum 
urea (Renal), patient age (Age), pleural fluid purulence (Purulence), infection source (community- 
versus healthcare-acquired Infection), and serum albumin (Dietary) were independently associated 
with mortality at three months.  Categorisation of patients into low- (RAPID score 0-2), medium- 
(RAPID score 3-4), and high-risk (RAPID score 5-7) groups was associated with mortality at 3 months 
of 3%, 9%, and 31% respectively (Table 1) (30).  
 
A robust prediction model for outcome in pleural infection would allow clinicians to risk stratify 
their patients, and inform further research assessing the use of invasive and/or expensive 
treatment strategies in higher-risk populations with the goal of improving long-term outcomes. This 
prospective study was conducted to test the hypothesis that the RAPID score at baseline predicts 
poor clinical outcome in adults with pleural infection. It evaluated whether the RAPID score could 
accurately predict mortality at three months (primary outcome), mortality at 12 months, medical 
treatment failure and need for surgical intervention based on objective criteria, length of hospital 






The Pleural Infection Longitudinal Outcome Study (PILOT) was a prospective observational cohort 
study in which adult patients with pleural infection were managed according to published 
guidelines (14, 15) adapted for usual local practice, and conducted in 29 centres in four countries 
(UK, USA, Australia, and South Africa) that together made up the PILOT Study Group.  
 
Subjects enrolled 
Study entry was offered to all participants fulfilling the entry criteria. Inclusion criteria were 
consistent with diagnostic criteria for pleural infection from national clinical guidelines (14, 15). 
Patients were included if they had a clinical presentation consistent with pleural infection and any 
of the following criteria: 
1. Pleural fluid that was macroscopically purulent, OR 
2. Pleural fluid that was positive on culture for bacterial infection, OR 
3. Pleural fluid that demonstrated bacteria on Gram staining, OR 
4. Pleural fluid with pH ≤7.2 (measured in a blood gas analyser) or low glucose level (≤3mmol/L 
or ≤55mg/dL)  in a patient with clinical evidence of infection, OR 
5. Contrast-enhanced CT evidence of pleural infection (consolidation of underlying lung with 
enhancing pleural collection) in a patient with clinical evidence of infection, alongside 
exclusion of other sources of infection. 
 
Evidence of infection was assessed by the recruiting physician on the basis of fever, an elevated 
peripheral blood white-cell count, or elevated serum inflammatory markers such as C-reactive 
protein (CRP).  
 
Study exclusion criteria were: 
1. Age less than 18 years, 
2. No pleural fluid available for analysis,  
3. Previous pneumonectomy on the side of pleural infection,  




The RAPID score (30) at baseline presentation was calculated according to the parameters in Table 
1. From the derived score, patients were placed in one of three risk categories (low, medium or 
high) pre-defined in the original paper (30) for the purposes of analysis. Individual patients did not 
have the RAPID score calculated or used to guide their clinical management during the study.  
 
Chest-tube drainage, antibiotic treatment, and investigations 
All decisions regarding patient management were left to the discretion of the responsible local 
clinicians who were asked to follow published national guidelines adapted to their usual practice. 
Advice for study investigators regarding chest tube size and insertion method (if deemed clinically 
appropriate), antibiotic choice, and other treatments for pleural infection was also provided in the 
study protocol (see online supplement) and based on widely available guidelines (14, 15). 
Radiological investigations included, as a minimum, a chest radiograph at study entry and at 
discharge from hospital, and (if appropriate) prior to referral for surgery. Thoracic ultrasound was 
conducted wherever possible at baseline, and the size of the pleural collection and extent of any 
septations scored (see online supplement for ultrasound scoring methodology). Spirometry was 
conducted at discharge from hospital, and at three months.  
 
Medical treatment failure and surgical referral 
As not all patients with pleural infection are considered fit enough to undergo surgical intervention, 
objective criteria for “medical treatment failure” were recorded in all cases. In brief, this required 
the presence of a significant residual pleural collection alongside clinical or biochemical features of 
uncontrolled infection such as ongoing fevers or persistently elevated inflammatory markers. These 
criteria were measured at three to five days post-study inclusion and recorded on the case report 
forms (CRF) (see online supplement). Current treatment guidelines (14, 15) do not describe 
detailed criteria on which to base surgical referral decisions for patients with pleural infection. 
Thus, guidance was provided to study investigators on referral for surgical intervention including 
meeting minimum objective criteria (see online supplement). The final decision to refer for surgery 
and to proceed with any subsequent operative intervention was at the discretion of the responsible 
local clinicians, with the reasons for surgical referral documented in CRFs thereafter.  
 
Follow Up 
All patients were followed up for 12 months; at three months they underwent assessment of the 
need for further drainage and/or surgical intervention, spirometry, and a chest radiograph.  Vital 




The primary outcome was all-cause mortality at 3 months post-study entry.  
 
Secondary Endpoints 
Secondary outcomes were:  
 All-cause mortality at 12 months, 
 Duration of hospital (in-patient) stay, 
 Need for surgical drainage of infected pleural fluid over 12 months, 
 Medical treatment failure, as defined by the study protocol (see online supplement), 
 Lung function at three months. 
 
Statistical Analysis 
Briefly, the description of participants’ characteristics, available predictors, and missing data were 
planned. Performance of the RAPID model was assessed with missing data imputed using multiple 
imputation by chained equations for missing predictors and missing outcomes (31). All available 
baseline variables were included in the imputation model. Predictive accuracy of the RAPID model 
was assessed using a variety of measures including discrimination, sensitivity, and specificity for 
each value of the RAPID score (0 to 7), and in each of the three risk categories (low, medium, and 
high). Discrimination was assessed using the C-statistic (32), and calculated separately for individual 
values of the RAPID score (0 to 7) and for the three risk categories. The C-statistic was also 
calculated and reported within pre-defined subgroups to assess consistent performance of the 
RAPID score. Analysis of secondary outcomes, with the exception of 12 month mortality, was based 
on complete case data. 
 
Sample size calculation 
Sample size calculations were based on the original study (n = 450) which provided the derivation 
and validation datasets for RAPID (30). In that study, a low-risk score (0-2; seen in 72% of patients) 
was associated with no deaths; medium-risk (3-4; 20% of patients) with 30% mortality; and high-
risk (5-7; 8% of patients) with 70% mortality (30). As a point estimate for the difference between 
low- and medium-risk groups, 96 subjects would be needed for this study (90% power, alpha 0.05). 
As this estimate was retrospectively derived and therefore likely over-optimistic, and would not 
exclude a minimum clinically significant difference, a minimum significant difference to detect 
mortality was fixed at 15%, i.e. low-risk mortality 15%, medium-risk 30% - with an unchanged (4:1) 
ratio of low- to medium-risk patients. Using these data, this study required 500 analyzable patients 
(90% power, alpha 0.05) and allowing for 10% loss to follow up (based on prior experience in 
carrying out clinical trials of pleural infection (10, 11)), a recruitment target of 550 patients was set. 
This study was reported according to the Transparent Reporting of a Multivariable Prediction 
Model for Individual Prognosis or Diagnosis (TRIPOD) statement (33).  
 
 
Ethical approval and registration 
Ethical and regulatory approval was obtained (Oxford B Research Ethics Committee Reference 







In total 551 participants were recruited. Five withdrew consent for use of their data during follow 
up; thus 546 were included in the final analysis (Figure 1). Baseline characteristics of the study 




The primary outcome measure (mortality at three months) was available for 542/546 (99.3%) study 
participants. At baseline missing prediction score parameters were: urea 21/546 (3.8%); age 9/546 
(1.6%); pleural fluid purulence 6/546 (1.1%); infection source 3/546 (0.5%); and albumin 29/546 
(5.3%). The RAPID score was well distributed across the study population (see online supplement) 
in both those who survived and those that died.  
 
Primary endpoint  
Mortality at three months was 54/542 (10.0%) and was strongly associated with the RAPID score; 
mortality increasing with each incremental rise in RAPID score (Figure 2). Analysis of patients 
according to their RAPID risk category (low, medium, and high) showed an increase in three month 
mortality according to risk category; low-risk (RAPID score 0-2) mortality was 5/222 (2.3%, 95% CI 
0.9 to 5.7), medium-risk (RAPID score 3-4) mortality 21/228 (9.2%, 95% CI 6.0 to 13.7), and high-risk 
(RAPID score 5-7) mortality 27/92 (29.3%, 95% CI 21.0 to 39.2). The hazard ratio for mortality at 
three months (with low-risk as the comparator) for medium-risk was 3.2 (95% CI 1.7 to 9.1, 
p<0·001), and for high-risk was 11.4 (95% CI 6.1 to 21.2, p<0·001). 
  
The Kaplan-Meier survival plot according to baseline RAPID risk category is shown in Figure 3. 
Discrimination of the predictive capability of the RAPID score for mortality at three and 12 months 
was 0.78 (95% CI 0.71 to 0.83) and 0.77 (95% CI 0.72 to 0.82) respectively. Sensitivity and specificity 





Mortality at 12 months was 102/542 (18.8%) patients. The 12-month mortality increased according 
to RAPID risk category; low-risk (RAPID score 0-2) mortality was 6.1% (95% CI 3.5 to 10.2), medium-
risk (RAPID score 3-4) mortality 18.0% (95% CI 13.6 to 23.3), and high-risk (RAPID score 5-7) 
mortality 49.9% (95% CI 39.8 to 60.0). Hazard ratios for mortality (with low-risk as the reference 
group) are shown in Table 3.  
 
Duration of Hospital Stay 
The median length of hospital stay across the study population was 13 days (IQR 7–23 days). The 
median length of hospital stay was significantly associated with baseline RAPID risk category (Table 
3).  
 
Medical treatment failure 
The failure of initial medical treatment was assessed in those with complete data, and occurred in 
158/472 (33.5%) patients; this was not significantly different according to baseline RAPID risk 
category (Table 3). The reasons for failure of initial medical treatment, per protocol guidance, are 
detailed in the online supplement and were not significantly different according to RAPID risk 
category. 
 
Need for surgical intervention within 12 months 
Overall, surgical intervention was required by 86/550 (15.6%) patients. The proportion of patients 
undergoing surgical intervention was significantly different according to RAPID risk category (Table 
3), as 19.1% of low-risk patients and 5.9% of high-risk patients underwent surgery. Analysing only 
those who met criteria for failure of initial medical treatment, there were significant differences in 
the number of patients undergoing surgery according to RAPID risk category, with surgery done in 
68.9% of low-risk, 31.5% of medium-risk, and 28.6% of high-risk patients. 
 
Lung Function at three months 
Lung function data were available in 154/540 (28.5%) patients only, limiting any detailed analysis. 
Significantly better lung function was observed in those in the low-risk RAPID category; this was 
seen in patients managed both medically and surgically (Table 3). 
 
Subgroup analyses 
Performance of the RAPID score was assessed in four predefined subgroups: ultrasound septation 
score, World Health Organisation performance status, presence of on-site thoracic surgery, and 
prior use of antibiotics. The model performed well in all subgroups, apart from those patients with 
severe septations on ultrasound (C-statistic 0.87 in the non-septated group, falling to 0.64 in the 
heavily septated group), or those with prior antibiotic use (fall in C-statistic from 0.82 to 0.69 in 
those with previous antibiotics) (see online supplement).  
 
Use of intrapleural fibrinolytic therapy 
82/546 (15.0%) patients were prescribed intrapleural fibrinolytic therapy by their responsible 
clinical team as part of their treatment for pleural infection. 62/82 (75.6%) patients received 
alteplase and dornase alfa; 20/82 (24.4%) patients received streptokinase.  There were no 
significant differences between the population of patients who received intrapleural fibrinolytics 
and those who did not with respect to baseline demographics or RAPID risk categorisation (Table 
4). Whilst there was a significant difference in three-month mortality between the two patient 
groups, this was not maintained out to 12-month follow-up (Table 5). The RAPID model performed 
well in both groups, with C-statistic 0.73 in those receiving intrapleural fibrinolytics and 0.78 in 





Results of the Pleural Infection Longitudinal Outcome Study (PILOT) demonstrate that at baseline 
the RAPID score allows adult patients with pleural infection to be stratified into different categories 
according to an increasing risk of three-month mortality. Patients were recruited based on 
commonly used clinical criteria for the diagnosis of pleural infection, while variables used to 
calculate the score are easily accessible to clinicians as part of routine clinical care at baseline 
presentation. As such, the score has clinical applicability, in a manner similar to clinical prediction 
scores used in management of pneumonia (34, 35). The fact that the RAPID score is strongly 
predictive of outcome in a study that recruited from a large number of centres varying in size, 
expertise, and geographical location, and despite local variations in clinical practice, further 
demonstrates its clinical utility. 
 
The performance of the RAPID risk categorisation in PILOT is remarkably similar to that seen in the 
original study (30) in which the RAPID score was first derived, then retrospectively validated. Three 
month mortality in the original study by risk group (low, medium, and high) was 3%, 9% and 31% 
respectively, and in PILOT was 2.3%, 9.3% and 30.8%. The PILOT study population mirrors that seen 
in other multicentre randomised studies with a similar ‘all-comers’ mortality of 20%, and surgical 
intervention rate of 16% (10, 11).  
 
Our results suggest a linear relationship between the RAPID score and three month mortality 
following  diagnosis of pleural infection, with scores ≤1 associated with 1.9% mortality and  scores 
≥6 associated with 35% mortality. It is not clear why all the parameters used in RAPID predict 
mortality so precisely; associations with increasing age, blood urea, and serum albumin are likely to 
identify a more frail population, and one in whom uncontrolled infection has resulted in a catabolic 
state.  
 
We postulate that the association of mortality with healthcare-acquired pleural infection is a result 
of more resistant organisms (36, 37) and potentially more co-morbid illness. An explanation for 
why non-purulent pleural fluid is associated with increased mortality remains unclear. Previous 
clinical didact, and a single case series, suggest that fluid purulence associates with poor outcome 
(9); however, these data were not prospectively derived. A lack of pleural fluid purulence may 
instead associate with abnormalities in the pleural space; either through increased septation and a 
more complex pleural space potentially related to deranged fibrinolytic activity (38, 39), or as a 
marker of poor pleural space neutrophil recruitment and immunity. 
 
The RAPID score appears to associate not only with mortality, but also with length of hospital stay. 
The score may predict those with pleural infection and complex treatment requirements, or simply 
reflect frailty of the population being treated, with increasing age and co-morbidity being intrinsic 
to the RAPID score. In this study a majority of deaths occurred within the first three months 
following diagnosis of pleural infection, as in previous studies (9, 10), suggesting that mortality is 
disease-specific and potentially amenable to improvement. 
 
The RAPID score appears to have validity among all subgroups assessed. There was no association 
between provision of on-site surgical services and RAPID prediction of mortality. Indeed, the 
proportion of patients who failed initial medical treatment (and, by extension, would be referred 
for consideration of surgical intervention) was similar across all RAPID groups. Despite this, use of 
surgical intervention was higher in the low-risk (19.1% of patients) than high-risk (5.9% of patients) 
group. In the high-risk group only one in three patients who objectively had failed medical 
treatment then underwent surgery; of these 30% subsequently died. These data might infer that 
surgical intervention is used most frequently in a low-risk group of patients with pleural infection 
(where mortality is low) and avoided in the highest risk group (where mortality is high). This high-
risk group commonly includes the elderly, where outcomes from pleural infection are poorest (7).  
 
As this is not a randomized study, it is not possible to speculate if surgical intervention itself is the 
reason for the lower mortality from pleural infection in the lowest risk group. However, it may be 
that potentially life-saving surgical treatment is avoided in the highest risk group despite a similar 
rate of objective medical treatment failure; a hypothesis lent weight by large surgical case series (5, 
37) which show a preference to intervene among younger individuals, with fewer co-morbidities 
than seen in unselected patient populations with pleural infection (10, 11). These results inform a 
pressing need for randomized studies in pleural infection, robustly powered to assess the impact of 
more invasive treatments, including surgical intervention, on mortality and other clinically 
important outcomes.  
 
Retrospective studies have identified the sonographic presence of septated pleural fluid as a 
potential predictor of outcome in pleural infection (29). Ultrasound was not used as part of the 
RAPID score as these parameters were not available in the derivation and validation datasets used 
to construct the score (30). Our results demonstrate the predictive ability of the RAPID score is 
reduced in the severely septated group as categorised by ultrasound. Although septations on 
ultrasound are often used as a surrogate for “non-draining” fluid, in reality they are often 
communicating spaces within the pleural cavity and their true significance  remains unknown. The 
presence of pleural fluid septations may be a marker for more significant disease, but not 
necessarily lack of drainage. For example, this might indicate worsened fibrinolytic activity in the 
pleural space (38, 39), or deep-seated and biofilm-forming infection (40). Recent data suggest that 
bacteria in pleural infection occupy a niche in the pleural lining rather than the fluid itself (41), and 
we postulate that the presence of septating effusion may facilitate bacterial growth and migration; 
these findings require further exploration. The true value of ultrasound assessment of the infected 
pleural space needs further study. Considering fluid septation in isolation ignores other 
sonographic features that may impact on outcome such as the size of a collection, presence of 
multiple locules of fluid, or pleural thickening.   
 
15% of patients recruited to this study were prescribed intrapleural fibrinolytic therapy by their 
responsible clinical team as part of their treatment for pleural infection, a sign of its increasing use 
as a routine intervention in this population. Our results show the RAPID score performed well in 
both patient groups, reflecting the fact that the score was originally developed using data from two 
randomised studies of intrapleural fibrinolytics (10, 11). An interesting observation was the 
significant difference in three-month mortality favouring those patients who received intrapleural 
fibrinolytics despite the two groups having similar baseline characteristics, although this difference 
was not preserved to 12-month follow-up. As this was not a randomized study specifically powered 
to assess the impact of intrapleural fibrinolytics on outcomes in pleural infection and the way in 
which fibrinolytics were used varied between centres, we cannot draw any firm conclusions.  
However, alongside previous work (11) the signal seen in this study raises the important question 
of whether mortality from pleural infection can be influenced by more invasive treatment and 
highlights the need for further research in this area of practice.  
 
As this study demonstrates RAPID to be a robust prediction score in pleural infection, how should it 
be used in practice? The score should be incorporated into future prospective studies of pleural 
infection to ensure balanced risks of mortality exist in study groups, and should also inform 
research assessing the safety and efficacy of new treatment paradigms – whether this is the use of 
less invasive, ambulatory strategies in the low-risk RAPID population (42, 43); or early invasive 
treatment such as surgery or intrapleural fibrinolytic therapy in the high-risk group.  Whilst it 
cannot yet direct clinical care or decision making, the RAPID score may also inform a clinician’s 
evidence-based discussions of the likely outcome from pleural infection at presentation and the 





The RAPID score uses data routinely available to a clinician at a patient’s baseline presentation with 
pleural infection in order to predict clinical meaningful outcomes.  Further studies targeting 
treatment according to RAPID risk categorisation are now required to better inform the treatment 
of adults with pleural infection, with the long-term aim of improving outcomes in a condition that 
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Figure 1: Flow chart describing the movement of patients through the study. 
Figure 2:  Three month mortality according to RAPID score at baseline. 
Figure 3:  Kaplan-Meier graphs censored for loss to follow up according to baseline RAPID risk 
category; based on a single representative imputed dataset. Low risk = RAPID score 0 
to 2; medium risk = RAPID score 3 to 4; high risk = RAPID score 5 to 7. Shaded areas 




Parameter Measure Score 
Renal Urea (mmol / L) <5.0 































Table 1. The RAPID risk prediction score, using baseline clinical parameters in patients with 


















Age, years - mean (SD) 60 (18) 
Male - no. (%) 385/545 (71%) 






Poor dental hygiene - no. (%) 100/545 (18%) 
Small (<15F) chest tube - no.  (%)  309/445 (70%) 
Antibiotic use before diagnosis - no. (%) 117/545 (21%) 
Pleural fluid characteristics  
Pleural fluid purulence - no. (%) 222/545 (41%) 
Gram stain or culture positivity - no. (%) 334/545 (61%) 
pH - median (IQR) 7.0 (6.8-7.2) 
LDH (U/L) - median (IQR) 1968 (946-5009) 
Coexisting illness – no. (%) 
Anticoagulation  259/540 (49%) 
Asthma 70/543 (13%) 
Atrial fibrillation 37/543 (7%) 
Cancer (current) 63/543 (12%) 
Cancer (previous) 59/543 (11%) 
COPD 70/543 (13%) 
Heart disease 47/543 (9%) 
Interstitial lung disease 10/543 (2%) 
Liver disease 28/543 (5%) 
Previous pleural infection 41/543 (8%) 
Renal 32/543 (6%) 
Diabetes 77/543 (14%) 
 
Table 2. Baseline characteristics of PILOT study participants 
  








12 month mortality  
(% (95% CI)) 
6.1 
(3.5 to 10.2) 
18.0 
(13.6 to 23.3) 
49.9 
(39.8 to 60.0) 
HR (versus low)   
Medium 3.2 (1.7 to 9.1), p<0.001 
High 11.4 (6.1 to 21.2), p<0.001 




(6 to 21) 
13  
(7 to 25) 
18  
(10 to 27) 
Mann Whitney 
p=0.003 
Failure of initial 
medical treatment  
(no, %, 95% CI) 
66 (35.1%) 
(28.3 to 41.9) 
70 (35.2%) 
(28.5 to 41.8) 
22 (25.9%) 
(16.6 to 35.2) 

2 3df = 2.68 
p=0.26 
Surgical intervention 
 (no, %, 95% CI) 
36 (19.1%) 
(13.5 to 24.8) 
31 (15.6%) 
(10.5 to 20.6) 
5 (5.9%) 
(0.9 to 10.9) 

2
 3df = 7.991 
p=0.02 
FEV1 at 3 months (L) 
(median (IQR)) 
-          overall popn 
 
-          non-surgical 
 
-          surgical 
  
 
2.4 (2.0 to 3.1) 
(n = 44) 
2.3 (2.0 to 3.1) 
(n = 40) 
2.7 (2.0 to 3.0)  
(n = 4) 
 
  
2.0 (1.6 to 2.4) 
(n = 53) 
2.0 (1.6 to 2.4) 
(n = 46) 
1.9 (1.3 to 2.3) 
(n = 7) 
  
 
1.9 (1.5 to 2.3) 
(n = 20) 
1.9 (1.5 to 2.3) 
(n = 19) 
2.3 (2.3 to 2.3)  






(calculated for overall popn only) 
FVC at 3 months (L) 
(median (IQR)) 
-          overall popn 
 
-          non-surgical 
 
  -          surgical 
  
 
3.5 (2.5 to 4.1) 
(n = 44) 
3.5 (2.5 to 4.1) 
(n = 40) 
3.6 (2.7 to 4.1) 
(n = 4) 
  
 
2.8 (2.2 to 3.4) 
(n = 53) 
2.8 (2.3 to 3.4) 
(n = 46) 
3.4 (1.7 to 3.5) 
(n = 7) 
  
 
2.8 (2.1 to 3.3) 
(n = 20) 
2.6 (2.0 to 3.2) 
(n = 19) 
3.5 (3.5 to 3.5) 






(calculated for overall popn only) 
 
 
Table 3.  Secondary outcomes according to baseline RAPID risk category. Lung function was 
available in 154 patients (FEV1) and 155 patients (FVC).  Analysis of 12 month 
mortality was based on multiple imputation: all other analyses were based on 
complete case data. 
  
Demographic characteristics No intrapleural 
fibrinolytic therapy 
N = 464 
Intrapleural 
fibrinolytic therapy 
N = 82 
Statistical 
comparison 
Age, years - mean (SD) 60.0 (17.2) 56.7 (15.6) unpaired t-test 
p=0.11 
Male - no. (%) 320/464 (69%) 65/82 (79%) χ2 1df = 3.08 
p=0.08 












 1df = 0.30 
p=0.58 













χ2 2df = 0.36 
p=0.84 
 
Table 4. Baseline characteristics of study participants who did and did not receive 
intrapleural fibrinolytic therapy 
 
  
 No intrapleural 
fibrinolytic therapy 
N = 464 
Intrapleural 
fibrinolytic therapy 
N = 82 
Statistical 
comparison 
3-month mortality - no. (%) 54/464 (11.6%) 0/82 (0%) Fisher’s exact test 
p=<0.001 
3-month C-statistic (95% CI) 0.78 (0.71 to 0.83) n/a  
 
12-month mortality - no. (%) 90/464 (19.4%) 12/82 (14.6%) Fisher’s exact test 
p=0.36  
12-month C-statistic (95% CI) 0.78 (0.71 to 0.83) 0.73 (0.57 to 0.84)  
 
 
Table 5. Three- and 12-month mortality and RAPID risk prediction model performance in 
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1. Chest tube drainage, antibiotic treatment, and other investigations 
Chest-tube drainage and antibiotic therapy 
If deemed to be clinically indicated by the responsible local clinical team, chest tube size and 
insertion method were at the discretion of the local study investigator according to local treatment 
and procedural guidelines. Smaller bore drains (<15Fr) were to be flushed regularly with sterile 
water or saline to maintain patency, and thoracic suction used where available. Fixation of the 
drain to the chest wall using sutures and dressings was advised to avoid early unintentional 
dislodgement. 
 
All patients received intravenous antibiotics initally which were chosen by the managing clinician 
(usually the local study investigator) in line with up-to-date evidence on the modern microbiology 
of pleural infection (see, for example, references 15, 34, 35 in the main manuscript) and local 
microbiological advice. Empiric antibiotic regimens according to the likely source (community vs. 
healthcare-acquired) of infection were suggested in a study-specific protocol - for example, co-
amoxiclav or a third-generation cephalosporin +/- metronidazole in community-acquired pleural 
infection; or a carbapenem with anti-pseudomonal activity plus vancomycin in healthcare-acquired 
infection. 
  
Antibiotic treatment was changed according to pleural fluid and/or blood culture and sensitivity 
results where available. Intravenous antibiotics were changed to oral consolidation therapy by the 
local study investigator and/or responsible clinician based on the clinical response to treatment. 
Empiric oral antibiotic consolidation regimens were suggested in a study-specific protocol; for 
example, co-amoxiclav +/- metronidazole in community-acquired infection; or a fluoroquinolone 
+/- clindamycin in healthcare-acquired infection. It was suggested that antibiotic treatment should 
be continued for a minimum of two weeks and up to six weeks (see reference 15 in the main 
manuscript) at the discretion of the local study investigator and according to clinical response; 
however, no minimum treatment duration of intravenous or oral antibiotics was mandated.  
 
Other treatments and investigations 
Repeat radiology and blood markers of infection were measured at the discretion of the local study 
investigator according to local best practice. As a minimum expectation, blood markers (including 
peripheral blood white-cell count and CRP) were conducted at baseline and prior to discharge, or at 
the point of referral for surgery if appropriate. The use of intrapleural therapeutic agents 
(fibrinolytic +/- DNase therapy) was at the discretion of the local study investigator and based on 
local guidelines, with their use recorded on the study Case Report Forms (CRFs). Thromboembolism 
prophylaxis whilst undergoing inpatient treatment for pleural infection was recommended in the 
study protocol, and was in accordance with local best practice.  
 
As a minimum expectation, a chest radiograph was conducted at study entry, at discharge from 
hospital, and prior to referral for surgery if appropriate. Thoracic CT scans and ultrasound were 
recommended during treatment and according to clinical need. Thoracic ultrasound was conducted 
wherever possible at baseline, and septations scored (please see later for ultrasound scoring 
methodology); and during the inpatient admission and/or follow-up thereafter as deemed 
appropriate  by the local study investigator. Spirometry was conducted at discharge from hospital, 
and at 3 months. 
 
  
2.  Suggested study criteria for referral for surgical intervention 
There are no agreed criteria on which to base surgical referral decisions for patients with pleural 
infection in current treatment guidelines (see references 14, 15 in main manuscript), or relating to 
the optimal timing of surgery in those patients who are failing “medical” treatment. This can lead 
to variation in local practice and decision making, the reasons for which might not always be clear 
without appropriate documentation in study CRFs. Guidance was therefore provided to all local 
study investigators on suggested criteria for referral for surgical intervention which included 
minimum objective criteria with the reasons for surgical referral to be documented on the CRFs. 
This guidance was based on recommendations made in published guidelines (see references 14, 15 
in main manuscript), recognising these were based on expert consensus. The minimum expected 
criteria for referral for surgical intervention were all of the following: 
 
1. At least 48 hours of medical treatment (including intercostal drainage of pleural collection 
and intravenous antibiotic therapy), unless significant clinical instability requiring more 
urgent intervention as judged by the local study investigator and/or responsible senior 
clinician. Reasons for an “early” decision to refer for surgery were recorded on the CRFs.  
2. Persisting evidence of sepsis, as demonstrated by clinical indicators (ongoing fever, or 
inflammation on blood indices), despite medical treatment as outlined above. 
3. A significant residual pleural fluid collection felt to be to contributing to the detriment of the 
patient and persisting sepsis as judged by the local study investigator and/or responsible 
senior clinician. 
 
The final decision on whether or not to refer for surgical intervention for a patient’s pleural 
infection remained with the local study investigator and/or responsible senior clinician, regardless 
of the suggested minimum study criteria, in order to best replicate usual local clinical practice and 




3.  Study criteria for Medical Treatment Failure 
The failure of medical treatment in pleural infection is most commonly marked by referral for 
surgical intervention in usual clinical practice. However, as not all patients with pleural infection are 
considered fit enough to undergo surgical intervention, objective criteria for “medical treatment 
failure” were recorded for all study participants in order to minimise the risk of any cases being 
otherwise missed. These were measured at 3-5 days post-study inclusion, and recorded on the 
CRFs as follows: 
 
 The presence of a residual and clinically significant pleural collection as judged by the local 
study investigator, based on current radiology (chest radiograph, ultrasound, and/or CT); plus 
at least one of the following:  
1) Clinical evidence of ongoing sepsis as demonstrated by factors such as otherwise 
unexplained persistent fever, tachycardia and/or hypotension; 
2) A serum CRP that has failed to fall by more than or equal to 50% compared to the baseline 
value prior to initiation of medical treatment for pleural infection; 
3) A lack of significant response in the peripheral blood white-cell count as judged by the 
local study investigator since the initiation of medical treatment for pleural infection. 
 
The question of whether or not medical treatment had failed had to be completed for all study 
participants between 3 and 5 days post-study inclusion; however, medical treatment failure could 
also be documented by the local study investigator at any point during a study participant’s 
treatment for their pleural infection up to and including 3-month follow-up. Local study 
investigators also had the option of documenting a free-text reason in the study CRFs as to why 




4.  Thoracic ultrasound scoring methodology 
Thoracic ultrasound was recommended at the time of initial chest tube insertion and during 
subsequent treatment according to clinical need. All patients underwent ultrasound assessment 
prior to pleural intervention by a respiratory or other physician holding Royal College of Radiology 
Thoracic Ultrasound level I competence or above. The size of the pleural effusion (small = visible in 
one rib space; moderate = two to three rib spaces; large ≥ four rib spaces), fluid echogenicity, and 
average number of septations per image field of view were recorded. Each effusion was 
categorized based on the initial sonographic findings into one of the following groups: non-
septated; mildly septated (<2 septations per field); moderately septated (2-4 septations per field); 
or severely septated (>4 per field). Visual scales of ultrasound pictures were included on the study 
CRFs to guide clinicians as to which score to use.  
 
 
5.  Study Delivery, Funding and Support 
Study delivery 
The study was coordinated by the Oxford Respiratory Trials Unit to standards of Good Clinical 
Practice, supervised by an independently chaired Study Steering Committee. Safety monitoring was 
risk assessed and not considered required, due to the observational nature of the study.  
 
Study funding and support 
The study was funded by the UK Medical Research Council (grant number G1001128). NMR was 
funded by the Oxford NIHR Biomedical Research Centre. Neither organization had influence on the 





1.  Distribution of the RAPID score across the recruited study population 
The RAPID score was well distributed across the study population as below, with an 




























2.  Documented reasons for failure of initial medical treatment 
The individual criteria which were met to classify a patient as having “failed medical treatment” are 
summarised in the table below – individual patients could have more than one reason for failure.  
 
Reason Low risk (n=188) Medium risk 
(n=199) 
High risk (n=85) Total (n=472) 
Physiological instability secondary to 
pleural infection 
9 13 3 25 
Clinical evidence of on-going sepsis 20 32 5 57 
Failure of inflammatory markers or WCC 
to improve sufficiently 
27 36 14 77 
Clinically significant residual collection 46 50 15 111 

















4.  Performance of the RAPID score by pre-specified subgroup analysis 
 
Subgroup Number in group Number died 
(%) 
C-statistic (95% CI) 
Ultrasound septation score 
Non-septated 80 10 (12.5) 0.87 (0.76, 0.94) 
Mild 63 11 (17.5) 0.84 (0.69, 0.92) 
Moderate 112 10 (8.9) 0.81 (0.67, 0.90) 
Severe 122 10 (8.2) 0.64 (0.46, 0.78) 
WHO performance status 
0 289 15 (5.2) 0.79 (0.66, 0.88) 
1 104 10 (9.6) 0.69 (0.52, 0.82) 
2 to 4 75 25 (33.3) 0.70 (0.57, 0.81) 
On site thoracic surgery 
Yes 262 29 (11.1) 0.75 (0.64, 0.83) 
No 207 21 (10.1) 0.82 (0.72, 0.88) 
Prior antibiotic use 
Yes 285 30 (10.5) 0.82 (0.75, 0.87) 




4.   Sensitivity and specificity for primary outcome (mortality at 3 months) using each level of 
the RAPID score 
 
RAPID score Sensitivity (95% CI) Specificity (95% CI) 
1 1.00 (1.00, 1.00) 0.02 (0.01, 0.03)  
2 0.98 (0.94, 1.00) 0.20 (0.16, 0.23) 
3 0.93 (0.85, 0.98) 0.43 (0.39, 0.48) 
4 0.72 (0.59, 0.83) 0.70 (0.66, 0.74) 
5 0.52 (0.39, 0.65) 0.86 (0.83, 0.89) 
6 0.13 (0.06, 0.22) 0.98 (0.96, 0.99) 
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